ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the same paper, we identified an important role of ERK5 in CML progenitor/stem cell maintenance and showed that ERK5 targeting in combination with the BCR/ABL inhibitor imatinib reduces the expression of the stem-cell-related factors NANOG, OCT4, and MYC [35,36].